The Alzheimer's Disease Neuroimaging Initiative 3: Continued innovation for clinical trial improvement

Michael W. Weiner, Dallas P. Veitch, Paul S. Aisen, Laurel A. Beckett, Nigel J. Cairns, Robert C. Green, Danielle Harvey, Clifford R. Jack, William Jagust, John C. Morris, Ronald C. Petersen, Jennifer Salazar (+4 others)
2017 Alzheimer's & Dementia  
INTRODUCTION- The overall goal of the Alzheimer's Disease Neuroimaging Initiative (ADNI) is to validate biomarkers for Alzheimer's disease (AD) clinical trials. ADNI-3, beginning August 1, 2016, is a five year renewal of the current ADNI-2 study. METHODS-ADNI-3 will follow current and additional subjects with normal cognition, mild cognitive impairment (MCI) and AD using innovative technologies such as tau imaging, magnetic resonance imaging (MRI) sequences for connectivity analyses, and a
more » ... y-automated immunoassay platform and mass spectroscopy approach for CSF biomarker analysis. A Systems Biology/Pathway approach will be used to identify genetic factors for subject selection/ enrichment. Amyloid positron emission tomography (PET) scanning will be standardized using by the Centiloid method. The Brain Health Registry will help recruit subjects and monitor subject cognition. RESULTS-Multi-modal analyses will provide insight into AD pathophysiology and disease progression. DISCUSSION-ADNI-3 will aim to inform AD treatment trials and facilitate development of AD disease-modifying treatments.
doi:10.1016/j.jalz.2016.10.006 pmid:27931796 pmcid:PMC5536850 fatcat:sutbyvnlqrhtrbexozepcvsimi